Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 851 to 900 of 921

Sort by

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)	TA207	27 October 2010	27 October 2010
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C	TA200	22 September 2010	22 September 2010
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis	TA199	25 August 2010	25 August 2010
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	TA195	25 August 2010	25 August 2010
Capecitabine for the treatment of advanced gastric cancer	TA191	28 July 2010	28 July 2010
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer	TA192	28 July 2010	28 July 2010
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia	TA193	28 July 2010	28 July 2010
Human growth hormone (somatropin) for the treatment of growth failure in children	TA188	26 May 2010	26 May 2010
Infliximab and adalimumab for the treatment of Crohn's disease	TA187	19 May 2010	19 May 2010
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes	TA47	5 September 2002	1 March 2010
Topotecan for the treatment of relapsed small-cell lung cancer	TA184	25 November 2009	25 November 2009
Topotecan for the treatment of recurrent and stage IVB cervical cancer	TA183	28 October 2009	28 October 2009
Guidance on the use of electroconvulsive therapy	TA59	26 April 2003	1 October 2009
Sunitinib for the treatment of gastrointestinal stromal tumours	TA179	23 September 2009	23 September 2009
Pemetrexed for the first-line treatment of non-small-cell lung cancer	TA181	23 September 2009	23 September 2009
Etanercept and efalizumab for treating moderate to severe plaque psoriasis	TA103	26 July 2006	1 September 2009
Alitretinoin for the treatment of severe chronic hand eczema	TA177	26 August 2009	26 August 2009
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma	TA178	26 August 2009	26 August 2009
Tenofovir disoproxil for the treatment of chronic hepatitis B	TA173	22 July 2009	22 July 2009
Rituximab for the first-line treatment of chronic lymphocytic leukaemia	TA174	22 July 2009	22 July 2009
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery	TA170	22 April 2009	22 April 2009
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma	TA169	25 March 2009	25 March 2009
Amantadine, oseltamivir and zanamivir for the treatment of influenza	TA168	25 February 2009	25 February 2009
Machine perfusion systems and cold static storage of kidneys from deceased donors	TA165	28 January 2009	28 January 2009
Infliximab for acute exacerbations of ulcerative colitis	TA163	17 December 2008	17 December 2008
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin	TA159	22 October 2008	22 October 2008
Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery	TA157	24 September 2008	24 September 2008
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza	TA158	24 September 2008	24 September 2008
Routine antenatal anti-D prophylaxis for women who are rhesus D negative	TA156	27 August 2008	27 August 2008
Entecavir for the treatment of chronic hepatitis B	TA153	27 August 2008	27 August 2008
Telbivudine for the treatment of chronic hepatitis B	TA154	27 August 2008	27 August 2008
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus	TA151	23 July 2008	23 July 2008
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck	TA145	25 June 2008	25 June 2008
Adalimumab for treating moderate to severe plaque psoriasis	TA146	25 June 2008	25 June 2008
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)	TA148	25 June 2008	25 June 2008
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)	TA149	25 June 2008	25 June 2008
Structural neuroimaging in first-episode psychosis	TA136	27 February 2008	27 February 2008
Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma	TA137	27 February 2008	27 February 2008
Infliximab for treating moderate to severe plaque psoriasis	TA134	23 January 2008	23 January 2008
Pemetrexed for the treatment of malignant pleural mesothelioma	TA135	23 January 2008	23 January 2008
Bortezomib monotherapy for relapsed multiple myeloma	TA129	23 October 2007	23 October 2007
Stapled haemorrhoidopexy for the treatment of haemorrhoids	TA128	26 September 2007	26 September 2007
Pemetrexed for the treatment of non-small-cell lung cancer	TA124	22 August 2007	22 August 2007
Varenicline for smoking cessation	TA123	25 July 2007	25 July 2007
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma	TA121	27 June 2007	27 June 2007
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia	TA119	28 February 2007	28 February 2007
Methadone and buprenorphine for the management of opioid dependence	TA114	24 January 2007	24 January 2007
Naltrexone for the management of opioid dependence	TA115	24 January 2007	24 January 2007
Gemcitabine for the treatment of metastatic breast cancer	TA116	24 January 2007	24 January 2007
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy	TA117	24 January 2007	24 January 2007

Results per page

10
25
50
All